Compendium of Cancer Genome Aberrations

Changes

Translocations et al. in Hematological Cancers (view source)

Revision as of 11:45, 26 August 2016

9 bytes removed ,  11:45, 26 August 2016
no edit summary
Line 1: Line 1:  +
==Acknowledgement==
 +
This list is based on the [http://www.mayomedicallaboratories.com/articles/features/hem-cyto/index.html '''Mayo Clinic Hematologic Cytogenetics Reference Sheet, November 2012'''].
 +
 
__TOC__
 
__TOC__
   Line 15: Line 18:  
|-
 
|-
 
|[[Translocation t(1;3)(p36;q21)|t(1;3)(p36;q21)]]
 
|[[Translocation t(1;3)(p36;q21)|t(1;3)(p36;q21)]]
−
|[[MDS]],[[ AML]]
+
|[[MDS]],[[AML]]
 
|[[PRDM16(MEL1)-RPN1]]
 
|[[PRDM16(MEL1)-RPN1]]
 
|-
 
|-
−
|[[t(1;3;5)(p36;p21;q33) ]]
+
|[[t(1;3;5)(p36;p21;q33)]]
 
|[[CEL]]
 
|[[CEL]]
 
|[[WDR48-PDGFRB]]
 
|[[WDR48-PDGFRB]]
Line 27: Line 30:  
|-
 
|-
 
|[[t(1;5)(q22;q33)]]
 
|[[t(1;5)(q22;q33)]]
−
|[[MPD with eosinophilia]],[[ CEL]],[[ B-ALL]]
+
|[[MPD]],[[ CEL]],[[ B-ALL]]
 
|[[PDE4DIP-PDGFRB]]
 
|[[PDE4DIP-PDGFRB]]
 
|-
 
|-
 
|[[der(1;7)(q10;p10)]]
 
|[[der(1;7)(q10;p10)]]
−
|[[MDS]],[[ AML]],[[ MPD]]
+
|[[MDS]],[[AML]],[[ MPD]]
 
|
 
|
 
|-
 
|-
 
|[[t(1;8)(p13;q24.1)]]  
 
|[[t(1;8)(p13;q24.1)]]  
 
|
 
|
−
|[[MYC(C-MYC)]]
+
|[[MYC]]
 
|-
 
|-
 
|[[t(1;14)(q21;q32)]]
 
|[[t(1;14)(q21;q32)]]
−
|[[B-ALL]],[[ NHL]]
+
|[[B-ALL]],[[NHL]]
−
|[[BCL9-IGH]],[[ FCGR2B-IGH]],[[ FCRL4-IGH]],[[ MUC1/IGH]]
+
|[[IGH-BCL9]],[[IGH-FCGR2B]],[[IGH-FCRL4]],[[IGH-MUC1]]
 
|-
 
|-
 
|[[t(1;19)(q23;p13.3) ]]
 
|[[t(1;19)(q23;p13.3) ]]
 
|[[B-ALL]]
 
|[[B-ALL]]
−
|[[PBX1-TCF3(E2A)]]
+
|[[TCF3(E2A)-PBX1]]
 
|-
 
|-
 
|[[Translocation der(16)t(1;16)(q21;q11.2)|der(16)t(1;16)(q21;q11.2)]]
 
|[[Translocation der(16)t(1;16)(q21;q11.2)|der(16)t(1;16)(q21;q11.2)]]
Line 55: Line 58:  
|-
 
|-
 
|[[t(2;5)(p23;q35)]]
 
|[[t(2;5)(p23;q35)]]
−
|[[ALCL]],[[ NHL]]
+
|[[ALCL]],[[NHL]]
 
|[[NPM1-ALK]]
 
|[[NPM1-ALK]]
 
|-
 
|-
 
|[[t(2;8)(p12;q24.1)]]
 
|[[t(2;8)(p12;q24.1)]]
−
|[[BL]],[[ B-ALL]],[[ NHL ]]
+
|[[BL]],[[ B-ALL]],[[NHL]]
−
|[[MYC(C-MYC)]]
+
|[[MYC]]
 
|-
 
|-
 
|[[t(2;11)(p21;q23)]]
 
|[[t(2;11)(p21;q23)]]
 
|[[MDS]],[[AML]],[[B-ALL]]
 
|[[MDS]],[[AML]],[[B-ALL]]
−
|[[MLL]]
+
|[[KMT2A]]
 
|-
 
|-
 
|[[t(2;14)(p15;q32)]]
 
|[[t(2;14)(p15;q32)]]
−
|[[CLL]],[[ NHL]],[[ B-ALL]],[[ T-ALL]],[[ AML]]
+
|[[CLL]],[[ NHL]],[[ B-ALL]],[[ T-ALL]],[[AML]]
 
|
 
|
 
|-
 
|-
−
|[[t(3;3)(q21;q26.2) ]]
+
|[[Translocation t(3;3)(q21;q26.2) and Inversion inv(3)(q21q26.2)|t(3;3)(q21;q26.2)]]
−
|[[MDS]],[[ AML]]
+
|[[MDS]],[[AML]]
 
|[[RPN1-MECOM(EVI1)]]
 
|[[RPN1-MECOM(EVI1)]]
 
|-
 
|-
Line 84: Line 87:  
|[[t(4;11)(q21;q23)]]
 
|[[t(4;11)(q21;q23)]]
 
|[[B-ALL]],[[ T-ALL]]
 
|[[B-ALL]],[[ T-ALL]]
−
|[[KMT2A(MLL)-AFF1(AF4)]]
+
|[[KMT2A-AFF1]]
 
|-
 
|-
 
|[[t(4;14)(p16.3;q32)]]
 
|[[t(4;14)(p16.3;q32)]]
Line 95: Line 98:  
|-
 
|-
 
|[[t(4;5;5)(q23;q31;q33)]]
 
|[[t(4;5;5)(q23;q31;q33)]]
−
|[[chronic basophilic leukemia]]
+
|[[Chronic Basophilic Leukemia]]
 
|[[PRKG2-PDGFRB]]
 
|[[PRKG2-PDGFRB]]
 
|-
 
|-
Line 111: Line 114:  
|-
 
|-
 
|[[t(5;12)(q33;q24)]]
 
|[[t(5;12)(q33;q24)]]
−
|[[MPD with eosinophilia  ]]
+
|[[MPD]]
 
|[[GIT2-PDGFRB]]
 
|[[GIT2-PDGFRB]]
 
|-
 
|-
 
|[[t(5;12)(q33;p13)]]
 
|[[t(5;12)(q33;p13)]]
−
|[[CMML]],[[ MDS]],[[ MPD]]
+
|[[CMML]],[[MDS]],[[MPD]]
 
|[[ETV6(TEL)-PDGFRB]]
 
|[[ETV6(TEL)-PDGFRB]]
 
|-
 
|-
 
|[[t(5;14)(q33;q24)]]
 
|[[t(5;14)(q33;q24)]]
−
|[[MPD]],[[ atypical MPD]]
+
|[[MPD]],[[MPD]]
 
|[[NIN-PDGFRB]]
 
|[[NIN-PDGFRB]]
 
|-
 
|-
Line 125: Line 128:  
|
 
|
 
|[[CCDC88C(KIAA1509)-PDGFRB]]
 
|[[CCDC88C(KIAA1509)-PDGFRB]]
−
|
   
|-
 
|-
 
|[[t(5;15)(q33;q22)]]
 
|[[t(5;15)(q33;q22)]]
−
|[[CMML atypical MPD]]
+
|[[CMML]],[[MPD]]
 
|[[TP53BP1-PDGFRB]]
 
|[[TP53BP1-PDGFRB]]
 
|-
 
|-
Line 140: Line 142:  
|-
 
|-
 
|[[der(5;17)(p10;q10)]]
 
|[[der(5;17)(p10;q10)]]
−
|[[MDS]],[[ AML]]
+
|[[MDS]],[[AML]]
 
|[[NPM1(NPM)-RARA]]
 
|[[NPM1(NPM)-RARA]]
 
|-
 
|-
Line 148: Line 150:  
|-
 
|-
 
|[[t(5;17)(q33;p13)]]
 
|[[t(5;17)(q33;p13)]]
−
|[[CMML]],[[ atypical MPD]]
+
|[[CMML]],[[MPD]]
 
|[[RABEP1-PDGFRB ]]
 
|[[RABEP1-PDGFRB ]]
 
|-
 
|-
Line 156: Line 158:  
|-
 
|-
 
|[[t(6;9)(p23;q34) ]]
 
|[[t(6;9)(p23;q34) ]]
−
|[[MDS]],[[ AML]]
+
|[[MDS]],[[AML]]
 
|[[DEK-NUP214 (CAN)]]
 
|[[DEK-NUP214 (CAN)]]
 
|-
 
|-
 
|[[t(6;11)(q27;q23) ]]
 
|[[t(6;11)(q27;q23) ]]
−
|[[AML]],[[ t-AML]],[[ T-ALL]]
+
|[[AML]],[[ t-AML]],[[T-ALL]]
−
|[[MLLT4(AF6)-MLL]]
+
|[[KMT2A-MLLT4]]
 
|-
 
|-
 
|[[t(7;11)(p15;p15)]]
 
|[[t(7;11)(p15;p15)]]
Line 169: Line 171:  
|[[t(8;14)(q24.1;q32) ]]
 
|[[t(8;14)(q24.1;q32) ]]
 
|[[BL]],[[ B-ALL]],[[ NHL]]
 
|[[BL]],[[ B-ALL]],[[ NHL]]
−
|[[MYC(C-MYC)- IGH]]
+
|[[IGH-MYC]]
 
|-
 
|-
−
|[[t(8;16)(p11.2;p13.3) A]]
+
|[[t(8;16)(p11.2;p13.3)]]
−
|[[AML M4]],[[ M5a]],[[ M5b]],[[ t-MDS]]
+
|[[AML]],[[t-MDS]]
 
|[[KAT6A(MYST3)-CREBBP(CBP)]]
 
|[[KAT6A(MYST3)-CREBBP(CBP)]]
 
|-
 
|-
 
|[[t(8;21)(q22;q22) A ]]
 
|[[t(8;21)(q22;q22) A ]]
−
|[[AML M2 mostly]],[[ rarely M1]],[[ M4]]
+
|[[AML]]
 
|[[RUNX1(AML)-RUNX1T1(ETO)]]
 
|[[RUNX1(AML)-RUNX1T1(ETO)]]
 
|-
 
|-
 
|[[t(8;22)(q24.1;q11.2) ]]
 
|[[t(8;22)(q24.1;q11.2) ]]
−
|[[BL]],[[ B-ALL]],[[ NHL]],[[ MM]]
+
|[[BL]],[[ B-ALL]],[[NHL]],[[ MM]]
−
|[[MYC(C-MYC)-IGL(IGL)]]
+
|[[IGL-MYC]]
 
|-
 
|-
 
|[[add(9)(p24)]]
 
|[[add(9)(p24)]]
Line 188: Line 190:  
|-
 
|-
 
|[[t(9;11)(p22;q23)]]
 
|[[t(9;11)(p22;q23)]]
−
|[[AML mostly M5]],[[ M4]],[[ B-ALL]]
+
|[[AML]],[[B-ALL]]
−
|[[MLLT3(AF9)-MLL]]
+
|[[KMT2A-MLLT3]]
 
|-
 
|-
 
|[[t(9;14)(p13;q32)]]
 
|[[t(9;14)(p13;q32)]]
−
|[[MM]],[[ CLL]],[[ DLBCL]],[[ FL]],[[ MCL splenic MZL]]
+
|[[MM]],[[CLL]],[[DLBCL]],[[FL]],[[MCL splenic MZL]]
 
|[[PAX5-IGH]]
 
|[[PAX5-IGH]]
 
|-
 
|-
−
|[[t(9;22)(q34;q11.2) A B ]]
+
|[[t(9;22)(q34;q11.2)]]
−
|[[CML]],[[ B-ALL]],[[ T-ALL]]
+
|[[CML]],[[ B-ALL]],[[T-ALL]]
 
|[[ABL1(ABL)-BCR]]
 
|[[ABL1(ABL)-BCR]]
 
|-
 
|-
−
|[[t(11;14)(q13;q32) A ]]
+
|[[t(11;14)(q13;q32)]]
 
|[[MCL]],[[ MM]]
 
|[[MCL]],[[ MM]]
−
|[[CCND1(BCL1)- IGH]]
+
|[[IGH-CCND1]]
 
|-
 
|-
 
|[[t(11;14)(q23;q32)]]
 
|[[t(11;14)(q23;q32)]]
−
|[[t-AML]]
+
|[[AML]]
−
|[[MLL-KIAA0284]]
+
|[[KMT2A-KIAA0284]]
 
|-
 
|-
 
|[[t(11;16)(q23;p13.3)]]
 
|[[t(11;16)(q23;p13.3)]]
Line 219: Line 221:  
|[[BIRC3(API2)-MALT1]]
 
|[[BIRC3(API2)-MALT1]]
 
|-
 
|-
−
|[[t(11;19)(q23;p13.1) ]]
+
|[[t(11;19)(q23;p13.1)]]
 
|[[AML]]
 
|[[AML]]
−
|[[MLL-ELL]]
+
|[[KMT2A-ELL]]
 
|-
 
|-
−
|[[t(11;19)(q23;p13.3) ]]
+
|[[t(11;19)(q23;p13.3)]]
−
|[[B-ALL]],[[ AML]],[[ T-ALL]]
+
|[[B-ALL]],[[AML]],[[T-ALL]]
−
|[[MLL-MLLT1(ENL)]]
+
|[[KMT2A-MLLT1]]
 
|-
 
|-
 
|[[t(14;16)(q32;q23)]]
 
|[[t(14;16)(q32;q23)]]
Line 231: Line 233:  
|[[IGH-MAF]]
 
|[[IGH-MAF]]
 
|-
 
|-
−
|[[t(14;18)(q32;q21) ]]
+
|[[t(14;18)(q32;q21)]]
−
|[[BL]],[[ DLBCL]],[[ FL]],[[ CLL]]
+
|[[BL]],[[DLBCL]],[[FL]],[[CLL]]
 
|[[IGH-BCL2]]
 
|[[IGH-BCL2]]
 
|-
 
|-
 
|[[t(14;19)(q32;q13.3)]]
 
|[[t(14;19)(q32;q13.3)]]
−
|[[CLL]],[[ DLBCL]],[[ MCL]],[[ MZL]],[[ SLVL]]
+
|[[CLL]],[[DLBCL]],[[MCL]],[[MZL]],[[SLVL]]
−
|
+
|[[IGH-BCL3]]
 
|-
 
|-
 
|[[t(14;19)(q32;q13)]]
 
|[[t(14;19)(q32;q13)]]
Line 273: Line 275:  
|'''GENES'''
 
|'''GENES'''
 
|-
 
|-
−
|[[inv(3)(q21q26.2) ]]
+
|[[Translocation t(3;3)(q21;q26.2) and Inversion inv(3)(q21q26.2)|inv(3)(q21q26.2)]]
 
|[[MDS]],[[ AML]]
 
|[[MDS]],[[ AML]]
 
|[[RPN1-MECOM(EVI1)]]
 
|[[RPN1-MECOM(EVI1)]]
Line 354: Line 356:  
|-
 
|-
 
|[[i(11)(q10) ]]
 
|[[i(11)(q10) ]]
−
|[[AML M2]],[[AML M4]],[[ MDS]]
+
|[[AML]],[[AML]],[[ MDS]]
 
|
 
|
 
|-
 
|-
 
|[[i(17)(q10)]]
 
|[[i(17)(q10)]]
−
|[[MDS]],[[ MPD]],[[ AML]],[[ CML]],[[ B-ALL]],[[ CLL]],[[ Hodgkin and NHL]]
+
|[[MDS]],[[ MPD]],[[ AML]],[[ CML]],[[ B-ALL]],[[CLL]],[[ Hodgkin and NHL]]
 
|
 
|
 
|-
 
|-
 
|[[i(21)(q10)]]
 
|[[i(21)(q10)]]
−
|[[B-ALL]],[[ MDS]],[[ NHL]],[[ AML]],[[ CMML]]
+
|[[B-ALL]],[[ MDS]],[[ NHL]],[[AML]],[[ CMML]]
 
|
 
|
 
|-
 
|-
 
|[[idic(X)(q13)]]
 
|[[idic(X)(q13)]]
−
|[[AML M1]],[[ M2]],[[ M4]],[[ MDS]],[[ RARS]]
+
|[[AML]],[[MDS]],[[RARS]]
 
|[[XIST]]
 
|[[XIST]]
 
|}
 
|}
Line 385: Line 387:  
|[[t(X;14) and t(Y;14)]]
 
|[[t(X;14) and t(Y;14)]]
 
|[[B-ALL]]
 
|[[B-ALL]]
−
|[[IGH-CRLF2]]
+
|[[T(X;14) and t(Y;14)|IGH-CRLF2]]
 
|-
 
|-
 
|[[t(5;14)(q35;q32)]]
 
|[[t(5;14)(q35;q32)]]
Line 392: Line 394:  
|-
 
|-
 
|[[del(1)(p32p32)]]
 
|[[del(1)(p32p32)]]
−
|[[B-ALL]]
+
|[[T-ALL]]
 
|[[SIL(STIL)-TAL1]]
 
|[[SIL(STIL)-TAL1]]
 
|}
 
|}
Line 581: Line 583:  
|
 
|
 
|-
 
|-
−
|[[del(20)(q11.2q13.1)
+
|[[del(20)(q11.2q13.1)]]
 +
|
 +
|
 +
|-
 
|[[del(20)(q11.2q13.3)]]
 
|[[del(20)(q11.2q13.3)]]
 
|[[AML]],[[MDS]],[[MPD]]
 
|[[AML]],[[MDS]],[[MPD]]
 +
|
 
|-
 
|-
 
|[[ider(20)(p11.1)del(20)(q11.2q13.3)]]
 
|[[ider(20)(p11.1)del(20)(q11.2q13.3)]]
Line 630: Line 636:  
|-
 
|-
 
|[[+15]]
 
|[[+15]]
−
|Age related when sole anomaly or with -Y
+
|[[Age Related]] when sole anomaly or with [[-Y]]
 
|-
 
|-
 
|[[+19]]
 
|[[+19]]
Line 645: Line 651:  
|-
 
|-
 
|[[-Y ]]
 
|[[-Y ]]
−
|age related when sole anomaly
+
|[[Age Related]] when sole anomaly
    
|}
 
|}
Line 714: Line 720:  
|[[LMO2(Rhom2)-TRA]]
 
|[[LMO2(Rhom2)-TRA]]
 
|}
 
|}
−
  −
==Acknowledgements==
  −
This list is based on the Mayo clinic Hematologic Cytogenetics Reference Sheet, November 2012
 
Retrieved from "https://content.ccga.io/index.php/Special:MobileDiff/589...2093"